Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer

PLoS Medicine

Volumn 3, Issue 10, 2006, Pages 1865-1876

  Singh, Anju ^a   Misra, Vikas ^a   Thimmulappa, Rajesh K ^a   Lee, Hannah ^a   Ames, Stephen ^b   Hoque, Mohammad O ^c   Herman, James G ^b   Baylin, Stephen B ^b   Sidransky, David ^b,c   Gabrielson, Edward ^b   Brock, Malcolm V ^b   Biswal, Shyam ^a,b,d  

^a The Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CARBOPLATIN; CYTOPLASM PROTEIN; ETOPOSIDE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; ANTINEOPLASTIC AGENT; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; CANCER SURVIVAL; CELL PROTECTION; CONTROLLED STUDY; DETOXIFICATION; DRUG SENSITIVITY; GENE DELETION; GENE INACTIVATION; GENE INSERTION; GENE LOCUS; GENE LOSS; GENE REPRESSION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; OXIDATIVE STRESS; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; XENOBIOTIC METABOLISM; ADENOCARCINOMA; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; MUTATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MUTATION; NF-E2-RELATED FACTOR 2;

EID: 33750885385     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030420     Document Type: Article

References (37)

1. Spiro SG, Silvestri GA (2005) The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 11: 287-291.
2. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, et al. (1993) Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85: 897-901.
3. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320.
4. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7: 1798-1804.
5. Soini Y, Napankangas U, Jarvinen K, Kaarteenaho-Wiik R, Paakko P, et al. (2001) Expression of gamma-glutamyl cysteine synthetase in nonsmall cell lung carcinoma. Cancer 92: 2911-2919.
6. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
7. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, et al. (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114: 1248-1259.
8. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, et al. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196-5203.
9. So HS, Kim HJ, Lee JH, Lee JH, Park SY, et al. (2006) Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ. E-pub ahead of print.
10. Hayashi A, Suzuki H, Itoh K, Yamamoto M, Sugiyama Y (2003) Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310: 824-829.
11. Nguyen T, Sherratt PJ, Pickett CB (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43: 233-260.
12. Vollrath V, Wielandt AM, Iruretagoyena M, Chianale J (2006) Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J 395: 599-609.
13. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, et al. (2001) Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 173: 154-160.
14. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, et al. (2006) Nrf2 is a critical regulator of the innate mmune response and survival during experimental sepsis. J Clin Invest 116: 984-995.
15. Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, et al. (2005) Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 202: 47-59.
16. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98: 3410-3415.
17. Sporn MB, Liby KT (2005) Cancer chemoprevention: Scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2: 518-525.
18. Morito N, Yoh K, Itoh K, Hirayama A, Koyama A, et al. (2003) Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 22: 9275-9281.
19. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130-7139.
20. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941-10953.
21. Adams J, Kelso R, Cooley L (2000) The kelch repeat superfamily of proteins: Propellers of cell function. Trends Cell Biol 10: 17-24.
22. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, et al. (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A 101: 2040-2045.
23. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35: 238-245.
24. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, et al. (2006) Structural basis for defects of keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700.
25. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal Biochem 27: 502-522.
26. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60: 4894-4906.
27. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, et al. (1998) Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21: 308-319.
28. Yang TL, Su YR, Huang CS, Yu JC, Lo YL, et al. (2004) High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Genes Chromosomes Cancer 41: 250-256.
29. Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett JC, et al. (1999) Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 38: 46-54.
30. Gunduz E, Gunduz M, Ouchida M, Nagatsuka H, Beder L, et al. (2005) Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int J Oncol 26: 201-210.
31. Sekido Y, Fong KM, Minna JD (2003) Molecular genetics of lung cancer. Annu Rev Med 54: 73-87.
32. Knudson AG Jr (1985) Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45: 1437-1443.
33. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163-177.
34. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, et al. (2003) Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63: 312-318.
35. Hamilton D, Batist G (2004) Glutathione analogues in cancer treatment. Curr Oncol Rep 6: 116-122.
36. Karapetian RN, Evstafieva AG, Abaeva IS, Chichkova NV, Filonov GS, et al. (2005) Nuclear oncoprotein prothymosin alpha is a partner of Keap1: Implications for expression of oxidative stress-protecting genes. Mol Cell Biol 25: 1089-1099.
37. Sasaki H, Nonaka M, Fujii Y, Yamakawa Y, Fukai I, et al. (2001) Expression of the prothymosin-a gene as a prognostic factor in lung cancer. Surg Today 31: 936-938.